Aripiprazole IM depot as an option for the treatment of bipolar disorder

Kotzalidis, Georgios D.; Rapinesi, Chiara; Chetoni, Chiara; Filippis, Sergio De

doi:10.1080/14656566.2021.1910236

Cited by 2 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data have motivated some authors to think that Aripiprazole, alone or in combination with Lithium/VPA could be considered a valid option for maintenance treatment, especially in those patients that do not respond satisfactorily to classical mood stabilizers [ 128 ]. However, long-term studies are required to confirm the evidence of benefits from this combination in maintenance pharmacological schemes [ 129 ], and even more so when Aripiprazole is administered through long-acting injections [ 130 ]. In fact, most studies consider mania prevention as their main clinical outcome, heedless of antipolar states, general functioning, and global patient’s well-being [ 27 , 131 ].…”

Section: Lithium/vpa Plus Aripiprazolementioning

confidence: 99%

Pharmacological Strategies for Bipolar Disorders in Acute Phases and Chronic Management with a Special Focus on Lithium, Valproic Acid, and Atypical Antipsychotics

Carli

Weiss

Grenno

et al. 2023

View full text Add to dashboard Cite

Bipolar disorders (BDs) are a heterogeneous group of severe affective disorders generally described by the alternation of (hypo)manic, depressive, and mixed phases, with euthymic intervals of variable duration. BDs are burdened with high psychiatric and physical comorbidity, increased suicide risk and reduced life expectancy. In addition, BDs can progress into complicated forms (e.g., mixed states, rapid/irregular cycling), which are more difficult to treat and often require personalized pharmacological combinations. Mood stabilizers, particularly Lithium and Valproic acid (VPA), still represent the cornerstones of both acute and chronic pharmacotherapies of BDs. Lithium is the gold standard in BD-I and BDII with typical features, while VPA seems more effective for atypical forms (e.g., mixed-prevalence and rapid-cycling). However, despite appropriate mood stabilization, many patients show residual symptoms, and more than a half recur within 1-2 years, highlighting the need of additional strategies. Among these, the association of atypical antipsychotics (AAPs) with mood stabilizers is recurrent in the treatment of acute phases, but it is also being growingly explored in the maintenance pharmacotherapy. These combinations are clinically more aggressive and often needed in the acute phases, whereas simplifying pharmacotherapies to mood stabilizers only is preferable in the long-term, whenever possible. When mood stabilizers are not enough for maintenance treatment, Quetiapine and, less consistently, Aripiprazole have been proposed as the most advisable adjunctive strategies, for their safety and tolerability profiles. However, in view of the increased risk of serious adverse effects, a careful patient-centered balance between costs and benefits is mandatory.

show abstract